Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Nov 6;16(11):e73121.
doi: 10.7759/cureus.73121. eCollection 2024 Nov.

Inflammatory Pseudotumor of the Spleen in a Patient With Psoriatic Arthritis: A Diagnostic Challenge in the COVID-19 Era

Alexandros S Iliadis  1   2 , Triantafyllia Koletsa  1 , Periklis Vounotrypidis  3 , Athanasios Fassas  4 , Athanasios Apostolidis  1 , Stylianos Apostolidis  5 , Anastasia Fotiadou  2 , Prodromos Hytiroglou  1   2
Affiliations
Case Reports

Inflammatory Pseudotumor of the Spleen in a Patient With Psoriatic Arthritis: A Diagnostic Challenge in the COVID-19 Era

Alexandros S Iliadis et al. Cureus. .

Abstract

The baseline inflammatory microenvironment in various organs of patients, which is shaped by pre-existing conditions and circulating drugs at the time before viral antigen exposure, may affect the severity of coronavirus disease-19 (COVID-19) infection and the nature of its complications. Inflammatory pseudotumor (IPT) of the spleen may represent one such complication that merits further investigation. We describe the case of a patient, who was under long-term treatment with a tumor necrosis factor inhibitor (TNFi), for psoriatic arthritis (PsA) and developed an inflammatory mass in the spleen, accompanied by systemic manifestations. This occurred with a history of four doses of nucleoside-modified messenger RNA (modRNA) vaccination for COVID-19 and shortly after a SARS coronavirus-2 (SARS-CoV-2) infection. Histologic examination of the splenectomy specimen supported by a large array of immunohistochemical stains and subsequent clinicopathological correlation indicated the diagnosis of splenic IPT in an immunologically altered background, due to modifying medication, immunization, and infection. Our case speculates that IPT may represent an adverse event related to immunogenicity of SARS-CoV-2, following antigen exposure (at first by sequential modRNA COVID-19 vaccinations and additionally by natural infection), despite the potentially protective effect of treatment with a TNFi.

Keywords: covid-19; disease modifying anti-rheumatic drugs; inflammatory pseudotumor; mrna-based vaccine; psoriatic arthritis; rheumatic disease; sars-cov-2; spleen; tumor necrosis factor-α(tnf-α) inhibitor.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Cross-sectional imaging and gross features
A. Preoperative upper abdomen magnetic resonance imaging revealing a prominent splenic mass; B. The cut surface of the surgical specimen shows a protruding spheroid mass with well-defined borders, brownish color, and solid texture.
Figure 2
Figure 2. Histopathological features
A, B. Red pulp substrate with fibroblastic reaction and moderate to severe inflammatory infiltrates, including "foamy" and iron-laden histiocytes, plasma cells, and lymphocytes; C. Immunohistochemical stain for CD68 highlighting histiocytes (A: hematoxylin-eosin, 100x; B: hematoxylin-eosin, 200x; C: streptavidin-biotin, 100x)
See this image and copyright information in PMC

References

    1. Inflammatory pseudotumour (plasma cell granuloma) of lung, liver and other organs. Anthony PP. Histopathology. 1993;23:501–503. - PubMed
    1. Clinical features and correct diagnosis of macrophage activation syndrome. Cron RQ, Davi S, Minoia F, Ravelli A. Expert Rev Clin Immunol. 2015;11:1043–1053. - PubMed
    1. Defining COVID-19-associated hyperinflammatory syndrome in specific populations. Webb BJ. Lancet Rheumatol. 2021;3:0–11. - PMC - PubMed
    1. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Ann Rheum Dis. 2020;79:859–866. - PMC - PubMed
    1. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. Shealy DJ, Cai A, Staquet K, et al. MAbs. 2010;2:428–439. - PMC - PubMed

Publication types

LinkOut - more resources